BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
BioCentury | Apr 19, 2019
Finance

Hope for China’s academic spinouts

Peking University spinout Hope Medicine is one of the latest examples of a trend that sees academics from Chinese universities increasingly taking top roles in a biotech sector traditionally led by MNC veterans. The start-up...
BC Week In Review | Apr 11, 2019
Company News

Hope Medicine in-licenses Bayer’s BAY 1158061

Hope Medicine gained exclusive, worldwide rights from Bayer to develop and commercialize BAY 1158061 to treat male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Hope Medicine Inc. (Beijing,...
Items per page:
1 - 3 of 3